ORPH |

Open Orphan #ORPH – Pfizer successful Phase 2a human challenge trial

Rapid progress at Open Orphan #ORPH. In Pfizer’s recent quarterly update, CEO Albert Bourla, noted (on page 5) that one of the key highlights of Pfizer’s Q2 was the “Successful Phase 2a human challenge trial with RSV Adult vaccine candidate”. Although Pfizer have not mentioned Open Orphan by name and we have not formally announced […]

Open Orphan #ORPH – DNDi Phase II trial to support river blindness drug

Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) which is the world leader in testing vaccines and antivirals using human challenge clinical trials, announces a contract to supply consultancy services to support a Phase II trial in Onchocerciasis Disease, an infectious disease commonly known as river blindness. Venn Life Sciences […]

Andrew Hore – Quoted Micro 26 July 2021

AQUIS STOCK EXCHANGE Ecotricity has launched a 340p a share cash bid for Good Energy (GOOD). Ecotricity believes the combined group would be better placed to compete in the energy supply business. The Good Energy board rejects the bid. Arbuthnot Banking (ARBB) reported a bounce back in interim pre-tax profit from £200,000 to £3m. the […]

Open Orphan PLC #ORPH – NEJM Opinion Piece

The New England Journal of Medicine (NEJM) publishes editorial relating to Human Challenge Programme Open Orphan (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, confirms that an editorial opinion piece regarding the UK Government’s Human Challenge Programme has been published in the latest edition […]

Alan Green discusses Coinsilium #COIN $CINGF & Open Orphan #ORPH on his weekly Stockbox Media Research talk

Poolbeg Pharma #POLB – Admission to AIM and First day of trading

Poolbeg Pharma (AIM: POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model , is pleased to announce that admission of its entire issued share capital to trading on the AIM market of the London Stock Exchange will become effective and dealings will commence at 8.00 a.m. today under the ticker […]

Alan Green discusses inflation, Barclays #BARC, Lloyds #LLOY & Open Orphan #ORPH on the UK Investor Magazine podcast

Alan Green joins the UK Investor Magazine Podcast to discuss Barclays (LON:BARC), Lloyds (LON:LLOY) and Open Orphan (LON:ORPH). UK inflation rose to 2.5% in June up from 2.1% in May. Fuel prices were a large component of the rises as oil prices increased having cratered last year. The FTSE 100 slipped in the wake of […]

Open Orphan #ORPH – Exec Chairman Cathal Friel & Non Exec Director Prof. Brendan Buckley purchase shares

The Company announces that it has received notification that, on 14 July 2021, Cathal Friel, Executive Chairman of the Company, purchased 1,132,075 ordinary shares of 0.1 pence each in the capital of the Company (“Shares”) at a price of 26.5 pence per Share and that Prof. Brendan Buckley, Non-Executive Director of the Company, purchased 188,679 […]

Open Orphan #ORPH – AIM Schedule 1 update by Poolbeg Pharma plc

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , notes the AIM Schedule One released in relation to Poolbeg Pharma plc (“Poolbeg”) this morning, 14 July 2021 at 8.00 a.m. updating on Poolbeg’s admission to AIM […]

Open Orphan #ORPH – New Contract win for Open Orphan’s Breda office

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a new contract win of c. €900,000 with an existing customer for clinical trial management by our Breda, Netherlands office. Cathal Friel, Executive Chairman of Open […]